Each year on March 31, the Office of the U.S. Trade Representative (USTR) releases its National Trade Estimate Report on Foreign Trade Barriers (NTE), presenting the American position on major trade issues with other countries. The content of the Taiwan chapter often provides valuable insight into how the United States perceives current conditions in the bilateral trade relationship.
In the past, the chapter typically consisted largely of U.S. government complaints about certain Taiwanese trade policies and practices. A few decades ago, the U.S. focus was on intellectual property rights (IPR) violations in Taiwan — issues later resolved by Taiwanese progress in strengthening laws and enforcement regarding copyrights, trademarks, patents, and trade secrets. Those changes have since been viewed by Taiwan as a positive development in protecting its own technology and elevating its global reputation as a good business partner.
Later the biggest point of contention was Taiwan’s restrictions on the import of certain American meat products. Those limitations, defended by Taiwan on health-safety grounds, were regarded by the U.S. side as spurious and protectionist. The dispute caused the usual channel for trade negotiations with Taiwan — the “TIFA talks” under the Trade and Investment Framework Agreement — to be suspended for nearly six years over beef imports and later almost five years over pork until satisfactory resolutions were worked out.
During the Biden administration, the platform for trade negotiations with Taiwan was called the U.S.-Taiwan Initiative on 21st-Century Trade, which sought to put the relationship on a more cooperative footing. Some agreements were reached, but the full program was never completed.
With the advent of the second Trump administration and its emphasis on wielding tariffs as a weapon, the U.S. government took a harder line. Although Taiwan’s conclusion of a trade deal the United States took longer than was the case for some other leading Asian trading nations, the Taiwan negotiating team led by Vice Premier Cheng Li-chiun eventually brought home a settlement that met the main American demands while preserving Taiwan’s strong competitive position in terms of tariff levels and other provisions.
In the Taiwan portion of the newly issued 2026 NTE, that Agreement on Reciprocal Tariffs (ART), signed early this year, takes center stage. While USTR continues to cite areas of Taiwan’s regulatory practice needing improvement — many of them overlapping with AmCham Taiwan’s White Paper recommendations — on balance, the report adopts a more affirmative tone than most previous NTEs, shifting the narrative from complaints to agreed-upon implementation.
Reflecting the collaborative approach achieved through the ART, the NTE repeatedly refers to understandings reached with Taiwan to narrow policy differences. As one example, it notes that, under the ART, Taiwan will accept U.S. FDA marketing authorizations for pharmaceuticals and medical devices manufactured in the United States “without additional requirements for entry into Taiwan’s markets.” Similar commitments were included regarding such other areas as labor and environmental conditions, agricultural imports, and further IPR enhancement.
At the same time, Taiwan received such benefits from the ART as tariff relief, most-favored-nation treatment, and closer integration into U.S.-led industrial cooperation initiatives.
Although the negotiation process was long and often frustrating, AmCham sees hopeful signs that the result is forging an even stronger, tighter, mutually advantageous trade relationship.
